Natural disrupter of RNA G-quadruplexes, inhibiting G-quadruplex-dependent alternative splicing, stimulting the stomach lining and inducing vomiting

Novel selective inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2

Novel potent, selective, and orally bioavailable inverse agonist of the histamine H 3 receptor (H 3 R)

Prodrug of CEP-751 (KT-6587) as antitumor agent, inhibiting protein kinases

Novel potent ALK inhibitor

Novel potent ALK inhibitor. also inhibiting the insulin receptor

Novel highly selective TAF1 inhibitor

Novel modulator of cell death signal transduction pathways, reducing the cytotoxicity of anthrax lethal toxin (LT)

Broad-spectrum, fifth-generation cephalosporin antibiotic, inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall

beta-Lactamase-stable, broad-spectrum, third-generation cephalosporin antibiotic with antibacterial activity

Broad-spectrum fourth-generation cephalosporin antibiotic

Fourth-generation cephalosporin

Third-generation broad spectrum antibiotic against both gram-positive and gram-negative microorganisms

Broad-spectrum, beta-lactamase-resistant, second-generation cephalosporin antibiotic, inhibiting bacterial cell wall synthesis via inhibition of cross-linking of peptidoglycans

Second-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity

Third-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity

First-generation cephalosporin antibiotic and interleukin 15 inhibitor, specifically interacting with interleukin 15 (IL-15) receptor subunit α (IL-15Rα) and to inhibit IL-15-dependent TNF-α and IL-17 synthesis, showing inhibitory activity against all of

Novel highly selective inhibitor of multidrug resistance protein 4 (MRP4)

Potent Antagonist for the Human Thyrotropin Receptor (TSHR)

Highly permeable non-Pglycoprotein substrate

Novel anti-hepatitis B virus (HBV) agent

Novel photoaffinity probe for cyclin-dependent kinase (CDK) family

Novel potent inhibitor of cyclin-dependent kinases (CDKs) 2, 5, and 9, displaying activities across more than 60 cancer cell lines

Potent and selective ATP competitiive inhibitor of cycB-CDK1, cycE-CDK2, and cycD1-CDK4

Novel inhibitor of the cyclin-dependent kinase 9 (CDK9)

Highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity

Novel potent dual inhibitor of CDK9 and BET proteins with balanced activities of BRD4 (IC50 = 12.7 nM) and CDK9 (IC50 = 22.4 nM), as well as good antiproliferative activities on a small cancer cell panel

Novel Potent and Selective CDK9 Degrader for Targeting Transcription Regulation in Triple-Negative Breast Cancer

Novel CDK8 inhibitor

Novel CDK8 inhibitor